Alpine Immune Sciences (NASDAQ:
ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.41) by 31.71 percent. This is unchanged from the same period last year. The company reported quarterly sales of $7.03 million which beat the analyst consensus estimate of $3.52 million by 99.77 percent. This is a 25.09 percent decrease over sales of $9.39 million the same period last year.